Cashed-up Insmed keeps eye on market ball as Arikace strategy laid out
This article was originally published in Scrip
Executive Summary
Insmed recently grossed $25.7 million from a direct public offering of common stock, building on the company's $73.1 million cash and investment balance as of 30 June, while keeping its clinical studies on track for the antibiotic Arikace (inhaled liposomal amikacin) after clinical holds on US trials for the orphan lung disease treatment were lifted earlier this year.